R

Rezolute Bio

Develops monoclonal antibodies for rare diseases

Vice President - Global Supply Chain

Full-TimePosted on 10/18/2026
$290k - $340k+ Annual performance bonus + Stock options
Expert
Bachelor's, Master's, MBA
Redwood City, CA, USA
HybridBased in Redwood City; remote employees may travel domestically and internationally up to 50%.
Operations & LogisticsSupply Chain Management

About the job

Requirements
  • A B.S. in a related field is required.
  • At least 15 years of pharmaceutical or biotech supply chain experience, including 5–7 or more years in senior leadership with demonstrated executive experience at the Vice President or Executive Director level.
  • Hands-on experience building a supply chain function, its systems, procedures, and team in a late-phase-to-commercial biotech context.
  • Commercial launch experience with direct accountability for a launched product through commercial labeling and packaging, third-party logistics, specialty distribution, and specialty pharmacy channels.
  • Experience designing and leading a Sales and Operations Planning process from launch through commercial supply.
  • Experience leading the design and implementation of Good Manufacturing Practice and Sarbanes-Oxley-compliant enterprise resource planning inventory management systems.
  • Experience defining label, artwork, and packaging configurations and supply models for multi-country market entry.
  • Experience managing global clinical supply for pivotal studies, open-label extensions, and expanded access programs.
  • Experience implementing serialization and global trade compliance for temperature-regulated biologics.
  • Ability to lead through influence, act with agility, lead problem solving, and drive robust solutions; strong communication across all organizational levels, humility, and a sense of humor.
  • The position is based in Redwood City, California, and may require domestic and international travel up to 50% for remote employees.
Responsibilities
  • Design, develop, and implement the transition from a clinically oriented supply chain to an integrated global clinical and commercial supply chain supporting direct and partnered markets while maintaining agility appropriate to a late-stage rare-disease company.
  • Oversee clinical and commercial supply channels from storage of drug product after shipment from the manufacturing site through labeling, packaging, finished drug product, regional and country depots, third-party logistics operations, and distribution channels.
  • Manage supply chain elements of the current Plan of Record, including global investigational product supply to depots, sub-depots, and clinical sites for two advanced Phase 3 programs; prepare for pre-Biologics License Application activities and potential global launches; lead the Clinical Supply team; and own the Commercial Supply Chain Integrated Plan feeding each indication’s Integrated Launch Plan.
  • Lead the Sales and Operations Planning process with Commercial Operations, Market Access, Patient Services, Clinical Operations, Finance, and Global Manufacturing to establish consensus demand and supply plans, inventory targets, scenarios, cost of goods, and spend.
  • Own the finished drug product supply plan to global channels, from which the Vice President of Global Manufacturing derives the Manufacturing Plan.
  • Develop, implement, and maintain a Good Manufacturing Practice- and Sarbanes-Oxley-compliant enterprise resource planning inventory management system for end-to-end inventory visibility, lot traceability, and financial control across clinical and commercial supply.
  • Work with Commercial and Regulatory teams to define final labels, artwork, and product packaging configurations, and establish the artwork and labeling management process for country-by-country market entry and supply.
  • Serve as a forward-facing Launch Team member and own supply chain launch readiness, including launch inventory, channel readiness, third-party logistics and distributor onboarding, and integration with Commercial Patient Services to enable rapid patient access.
  • Partner with ex-U.S. Commercial and Regulatory teams to develop country-specific supply plans, packaging configurations, and distribution models for direct and partnered markets, including named-patient and early-access supply where applicable.
  • Establish a commercial distribution network, including selection and integration of third-party logistics providers, specialty distribution, and specialty pharmacy channels aligned with the Commercial channel strategy.
  • Establish logistics and global trade compliance capabilities for controlled, compliant cross-border movement of temperature-regulated products using validated means.
  • Implement a serialization and track-and-trace platform that complies with global regulations, including the Drug Supply Chain Security Act and the European Union Falsified Medicines Directive.
  • Identify and mitigate risks to product supply for clinical sites and global markets; routinely assess risks within the role’s control, implement mitigation plans, and escalate as appropriate.
  • Apply a governance structure with packaging, labeling, depot, third-party logistics, and distribution partners to ensure clear understanding of work, costs, risks, and deliverables.
  • Enable transfers and onboarding of labeling, packaging, depot, third-party logistics, and distribution service providers by establishing relationships and leading program, contract, and deliverable management; partner with Quality’s Manufacturing Science and Technology team, which owns technical specification, characterization, qualification, validation, and Module 3 authorship.
  • Support global submissions related to labeling, packaging, and distribution in coordination with Quality and Regulatory teams.
  • Work as part of the Technical Operations Leadership team, supporting open, honest communication and collaboration.
  • Build, lead, manage, and develop a high-performance, phase-appropriate team covering clinical supply, demand and supply planning, labeling and packaging, commercial distribution, logistics, and trade compliance.
  • Build phase-appropriate supply chain systems, procedures, and work instructions for planning, inventory management, labeling and packaging, distribution, and partner oversight.
  • Work with the Head of Quality to maintain integration with Quality processes, including Good Distribution Practice compliance, finished drug product disposition, temperature excursion management, complaints, returns, recall readiness, and vendor qualification.
  • Partner with the Vice President of Global Manufacturing to ensure seamless handoff of drug product into the global supply chain and alignment between the finished drug product supply plan and Manufacturing Plan.
  • Manage supply chain financial matters, including budgeting, forecasting, long-range planning, inventory levels and valuation with Finance, expiry and write-off management, and cost of goods for packaging and distribution.
  • Lead development of relationships and contracts with packaging, labeling, depot, third-party logistics, and distribution partners, negotiating to meet near- and long-term needs cost-effectively with Legal, Finance, Quality, and functional heads.
  • Establish supply chain key performance indicators, including service level, on-time-in-full, inventory health, and forecast accuracy, and report performance to the Technical Operations Leadership team and Launch Team.
Desired Qualifications
  • An advanced degree or Master of Business Administration is preferred.
  • Rare-disease experience is highly preferred.
  • Experience supporting ex-U.S. launches through direct and partnered models in the European Union and other regions.
  • Experience working directly with Commercial Patient Services and hub providers on patient access.
  • APICS/ASCM certification is a plus.
  • Experience with NetSuite is preferred.

About the company

Rezolute Bio develops therapies for rare diseases, aiming to address unmet needs in both pediatric and adult patients. Its lead candidate, RZ358, is a human monoclonal antibody in late-stage trials for congenital hyperinsulinism and works by binding to and inhibiting insulin to reduce hypoglycemic events. The company also pursues RZ402, an oral plasma kallikrein inhibitor for diabetic macular edema. Its goal is to bring approved therapies to patients by advancing late-stage programs toward commercialization and building a portfolio focused on rare diseases.

Company Size

51-200

Company Stage

IPO

Headquarters

Louisville, Kentucky

Founded

2010

Get referred to Rezolute Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PES 2026 analyses showed CGM hypoglycemia reductions above 50% versus placebo.
  • FDA accepted tumor HI development streamlining in September 2025, with topline data expected 2H 2026.
  • Cash and investments reached $120.3 million on March 31, 2026, supporting runway.

What critics are saying

  • SunRIZE missed primary and key secondary endpoints in December 2025, damaging approval odds.
  • FDA requested broader sunRIZE and extension datasets on March 17, 2026, delaying filing.
  • A December 2025 layoff cut 29 employees after the setback, signaling fragile execution.

What makes Rezolute Bio unique

  • Ersodetug targets insulin receptor signaling, addressing congenital and tumor hyperinsulinism downstream.
  • FDA granted Breakthrough Therapy Designation for congenital HI on January 7, 2025.
  • Rezolute paired ersodetug with commercial hires from Ultragenyx and Cytokinetics in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Disability Insurance
  • Life Insurance
  • Paid Holidays
  • Paid Vacation
  • 401(k) Plan Match
  • Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

1%

2 year growth

-1%
Africa Business Watch
Jul 21st, 2026
Rezolute to participate in the BTIG Virtual Biotechnology Conference.

Rezolute to participate in the BTIG Virtual Biotechnology Conference. REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their BTIG representative. About Rezolute, Inc. Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI). The Company's antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com. Rezolute Contacts: Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

The Manila Times
Apr 21st, 2026
Rezolute to present results from its Phase 3 sunRIZE study in congenital hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting.

Rezolute to present results from its Phase 3 sunRIZE study in congenital hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting. By GlobeNewswire April 21, 2026 Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that results from the Phase 3 sunRIZE study of ersodetug in congenital HI were accepted for an oral presentation at the Pediatric Endocrine Society (PES) Annual Meeting being held April 30-May 3, 2026, in San Francisco, CA. In addition to the previously reported topline results, the presentation will also include results from pre-specified and post-hoc sunRIZE analyses, which the Company believes continue to demonstrate target engagement and the therapeutic benefit of ersodetug. Presentation Title: Top-Line Results From a Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (sunRIZE) Format: Oral presentation Presenter: Diva D. De León-Crutchlow, MD, MSCE Session Date and Time: Friday, May 1, 2026, from 8:15 a.m. - 9:15 a.m. PT Session Title: Oral Abstracts #1 About sunRIZE The Phase 3 sunRIZE study (RZ358-301) was a multi-center, randomized, double-blind, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug in patients with congenital hyperinsulinism (HI), ages 3 months to 45 years old, who were experiencing continued hypoglycemia on currently available standard of care (SOC). Eligible participants were randomized to one of three treatment arms to receive either ersodetug (5 or 10 mg/kg) or matched placebo-control as add on to existing SOC. Study drug was administered every other week during an initial loading phase, and then every 4 weeks during the 6-month controlled pivotal treatment period. Following the pivotal treatment phase of the study, participants could roll-over into an optional open-label extension phase to continue to receive ersodetug. The study enrolled 63 participants in more than a dozen countries around the world, inclusive of U.S. patients. The primary and key secondary efficacy endpoints in the study were the change from baseline in the average number of hypoglycemia events per week and the average percent time in hypoglycemia, respectively, over six months of treatment. About Ersodetug Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com. Forward-Looking Statements This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to, the potential efficacy of ersodetug in treating hypoglycemia. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission's website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. Rezolute Contacts: Christen Baglaneas 508-272-6717 Carrie McKim 336-608-9706

The Manila Times
Mar 4th, 2026
Rezolute to Participate in the Citizens Life Sciences Conference

Rezolute to participate in the Citizens Life Sciences Conference. By GlobeNewswire March 4, 2026 REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Citizens Life Sciences Conference, taking place March 10-11, 2026, in Miami, FL. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Citizens representative. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com. Rezolute Contacts: Christen Baglaneas 508-272-6717 Carrie McKim powered by 336-608-9706

Rezolute, Inc.
Feb 4th, 2026
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rezolute to participate in the Guggenheim Emerging Outlook: Biotech Summit 2026. February 04, 2026 7:00 am EST Download as PDF REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place February 11-12, 2026 in New York. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com. Released February 4, 2026

Fierce Pharma
Aug 21st, 2025
Rezolute resolves commercial question, hiring ex-Ultragenyx exec to ready for rare disease launch

Karnawat joins Rezolute from Cytokinetics, where he spent just over a year as vice president of global value, access and distribution.